Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis

References

• Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999 juill 10;354(9173):93‑9.
   PubMed Web of Science ®Google Scholar
• Vajdic CM, McDonald SP, McCredie MRE, et al. Cancer incidence before and after kidney transplantation. Jama. 2006 déc 20;296(23):2823‑31.
   PubMed Web of Science ®Google Scholar
• Cucković C, Djukanović L, Janković S, et al. Malignant tumors in haemodialysis patients. Nephron. 1996;73(4):710‑2.
   PubMed Web of Science ®Google Scholar
• Matas AJ, Simmons RL, Kjellstrand CM, et al. Increased incidence of malignancy during chronic renal failure. Lancet. 1975 avr 19;1(7912):883‑6.
   Web of Science ®Google Scholar
• Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron. 1977;18(3):182–184.
   PubMed Web of Science ®Google Scholar
• Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol. 2002;33(1):121‑6.
   Google Scholar
• Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol. 2010 juin;23(3):253‑62.
   PubMed Web of Science ®Google Scholar
• Vogelzang JL, Van Stralen KJ, Noordzij M, et al. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant. 2015 juin;30(6):1028‑37.
   PubMed Web of Science ®Google Scholar
• Cheung CY, Chan GCW, Chan SK, et al. Cancer incidence and mortality in chronic dialysis population: a multicenter cohort study. Am J Nephrol. 2016;43(3):153‑9.
   PubMed Web of Science ®Google Scholar
• Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer? J Nephrol. 2008 avr;21(2):166‑74.
   PubMed Web of Science ®Google Scholar
• Janus N, Launay-Vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol. 2013 févr;24(2):501–507.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009 août;65(8):757–773..
   PubMed Web of Science ®Google Scholar
• Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep. 1999 oct;1(5):410–416.
   PubMedGoogle Scholar
• Ryss ES, Lutoshkin MB. Changes in the large intestine in patients with chronic kidney failure. Ter Arkh. 1996;68(6):33‑7.
   Web of Science ®Google Scholar
• Leblond FA, Petrucci M, Dubé P, et al. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol. 2002 juin;13(6):1579–1585.
   PubMed Web of Science ®Google Scholar
• Gibson TP. Renal disease and drug metabolism: an overview. Am J Kidney Dis. 1986 juill;8(1):7‑17.
   PubMed Web of Science ®Google Scholar
• Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol. 2010 avr;50(4):472–481.
   PubMed Web of Science ®Google Scholar
• Bowmer CJ, Lindup WE. Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem Pharmacol. 1982 févr 1;31(3):319‑23.
   Web of Science ®Google Scholar
• Launay-Vacher V, Storme T, Izzedine H, et al. Pharmacokinetic changes in renal failure. Presse Med. 2001 mars 31; 30(12):597‑604..
   PubMed Web of Science ®Google Scholar
• de Jongh FE, Van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003 avr 22;88(8):1199–1206.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010;10:50.
   PubMed Web of Science ®Google Scholar
• Fujita K, Masuo Y, Okumura H, et al. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm Res. 2016 févr;33(2):269–282.
   PubMed Web of Science ®Google Scholar
• Lam YW, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet. 1997 janv;32(1):30‑57.
   PubMed Web of Science ®Google Scholar
• Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet. 2010 sept;49(9):607–618.
   PubMed Web of Science ®Google Scholar
• Martin P, Oliver S, Kennedy S-J, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012 janv;34(1):221–237.
   PubMed Web of Science ®Google Scholar
• Sun H, Huang Y, Frassetto L, et al. Effects of uraemic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004 nov;32(11):1239‑46.
   PubMed Web of Science ®Google Scholar
• Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006 janv;109(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Iyer L, Ratain MJ. 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. 1999;17(7):494‑506.
   PubMed Web of Science ®Google Scholar
• Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010 juill;21(7):1395–1403.
   PubMed Web of Science ®Google Scholar
• Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol. 2002 mars;49(3):225‑34.
   PubMed Web of Science ®Google Scholar
• Prestayko AW, D’Aoust JC, Issell BF, et al. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 1979 mars;6(1):17‑39.
   Web of Science ®Google Scholar
• Tanabe N, Goto M, Morita H, et al. Pharmacokinetics of cis-diammine-dichlor-platin in a haemodialysis patient. Cancer Invest. 1991;9(6):629–635.
   PubMed Web of Science ®Google Scholar
• Gorodetsky R, Vexler A, Bar-Khaim Y, et al. Plasma platinum elimination in a haemodialysis patient treated with cisplatin. Ther Drug Monit. 1995 avr;17(2):203–206.
   PubMed Web of Science ®Google Scholar
• Kurisu A, Hata T, Owada A. Full-dose chemotherapy for esophageal cancer patient under haemodialysis. Nephron. 2002 déc;92(4):960.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer. 2003 janv 13;88(1):25‑30.
   Web of Science ®Google Scholar
• Naud J, Michaud J, Boisvert C, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther. 2007 mars;320(3):978‑85.
   PubMed Web of Science ®Google Scholar
• Naud J, Michaud J, Beauchemin S, et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos. 2011 août;39(8):1363‑9.
   PubMed Web of Science ®Google Scholar
• Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991 mars;9(3):491‑8.
   PubMed Web of Science ®Google Scholar
• Masumori N, Kunishima Y, Hirobe M, et al. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in haemodialysis patients with advanced urothelial cancer. Jpn J Clin Oncol. 2008 mars;38(3):182–185.
   PubMed Web of Science ®Google Scholar
• Kiani A, Köhne C-H, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard haemodialysis treatment. Cancer Chemother Pharmacol. 2003 mars;51(3):266‑70.
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007 janv;43(1):14‑34.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013 sept;76(3):432‑44.
   PubMed Web of Science ®Google Scholar
• Janus N, Launay-Vacher V, Karie S, et al. Vaccination and chronic kidney disease. Nephrol Dial Transplant. 2008 mars;23(3):800‑7.
   PubMed Web of Science ®Google Scholar
• Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet. 1992 juin;22(6):434–446.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Peoples GE. Injecting hope – a review of breast cancer vaccines. Oncology (Williston Park, NY). 2016 mai;30(5):475–81, 485.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol. 2010 nov;30(6):548–556..
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Tsuchiya K, Nitta K, et al. Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality. Nihon Jinzo Gakkai Shi. 2011;53(1):38‑45.
   Google Scholar
• Iff S, Craig JC, Turner R, et al. Reduced estimated GFR and cancer mortality. Am J Kidney Dis. 2014 janv;63(1):23‑30.
   Web of Science ®Google Scholar
• Chen J, Wang X-T, Luo P-H, et al. Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study. Support Care Cancer. 2015 avr;23(4):1043–1048.
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Cirrincione CT, Hurria A, et al. Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an ancillary study of CALGB/CTSU 49907. J Clin Oncol. 2016 mars 1;34(7):699–705.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RWF, Brundel DHS, Neef C, et al. Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013 févr;108(5):1071‑8.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RWF, Jansman FGA, van den Bemt PMLA, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015 mai;26(5):992‑7.
   Web of Science ®Google Scholar
• Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Pract. 2014 juill;10(4):e255–268.
   PubMedGoogle Scholar
• SiteGPR® [Internet]. Guide de prescription et rein. [cité 15 janv 2016]. Disponible sur: http://www.sitegpr.com
   Google Scholar